Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar-Apr;9(3-4):90-6.
doi: 10.5489/cuaj.2526.

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Fred Saad  1 , Kim N Chi  2 , Antonio Finelli  3 , Sebastien J Hotte  4 , Jonathan Izawa  5 , Anil Kapoor  6 , Wassim Kassouf  7 , Andrew Loblaw  8 , Scott North  9 , Ricardo Rendon  10 , Alan So  11 , Nawaid Usmani  12 , Eric Vigneault  13 , Neil E Fleshner  3
Affiliations

The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)

Fred Saad et al. Can Urol Assoc J. 2015 Mar-Apr.

Abstract

Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance of optimizing the use of these agents, a multidisciplinary team approach is highly recommended.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Management of castration-resistant prostate cancer (CRPC). PSADT: prostate-specific antigen doubling time. mCRPC: metastatic CRPC. *Pending Health Canada approval in the chemo-naïve setting.

  1. The optimal sequence of available options remains unknown.

  2. Patients who have had little no response to hormonal agents OR who progress with minimal change in PSA or with significant visceral metastases should be considered for early chemotherapeutic options.

  3. Radium-223 is not approved for patients with visceral metastases.

  4. Whenever possible, clinical trials should remain the first choice in patients with CRPC.

See this image and copyright information in PMC

References

    1. Mohler JL, Gregory CW, Ford OH, 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440–8. doi: 10.1158/1078-0432.CCR-1146-03. . - DOI - PubMed
    1. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26:1148–59. doi: 10.1200/JCO.2007.12.4487. . - DOI - PMC - PubMed
    1. Smith MR, Kabbinavar F, Saad F, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25. doi: 10.1200/JCO.2005.01.529. . - DOI - PubMed
    1. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583) J Clin Oncol. 2004;22:1025–33. doi: 10.1200/JCO.2004.06.037. . - DOI - PubMed
    1. Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) Eur Urol. 2014;66:815–25. doi: 10.1016/j.eururo.2014.02.056. . - DOI - PMC - PubMed